Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

High-dose interleukin-2 (HD IL-2) was approved in the 1990s after demonstrating durable complete responses (CRs) in some patients with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC). Patients who achieve this level of disease control have also demonstrated improved survival comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Joseph I, Curti, Brendan, Davis, Elizabeth J, Kaufman, Howard, Amin, Asim, Alva, Ajjai, Logan, Theodore F, Hauke, Ralph, Miletello, Gerald P, Vaishampayan, Ulka, Johnson, Douglas B, White, Richard L, Wiernik, Peter H, Dutcher, Janice P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020079/
https://www.ncbi.nlm.nih.gov/pubmed/33542072
http://dx.doi.org/10.1136/jim-2020-001650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020079/
https://www.ncbi.nlm.nih.gov/pubmed/33542072
http://dx.doi.org/10.1136/jim-2020-001650

Ejemplares similares